References
- Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:https://doi.org/10.1016/j.jaci.2014.08.042.
- Nagase H, Adachi M, Matsunaga K, Yoshida A, Okoba T, Hayashi N, Emoto K, Tohda Y. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69(1):53–60. doi:https://doi.org/10.1016/j.alit.2019.06.003.
- Nagase H. Severe asthma in Japan. Allergol Int. 2019;68(2):167–171. doi:https://doi.org/10.1016/j.alit.2019.02.004.
- Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020; 55:1900588. doi:https://doi.org/10.1183/13993003.00588-2019.
- Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomized, multicenter, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:https://doi.org/10.1016/S0140-6736(16)31324-1.
- FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, CALIMA study investigators, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:https://doi.org/10.1016/S0140-6736(16)31322-8.
- Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:https://doi.org/10.1056/NEJMoa1703501.
- Richards LB, van Bragt JJMH, Aarab R, Longo C, Neerincx AH, Sont JK, Weersink EJM, Braunstahl G-J, Brinke AT, Bel EHD, et al. Treatment eligibility of real-life mepolizumab-treated severe asthma patients. J Allergy Clin Immunol Pract. 2020;8(9):2999–3008. doi:https://doi.org/10.1016/j.jaip.2020.04.029.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018. Available from: www.ginasthma.org.
- Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med. 2009;103(11):1633–1642. doi:https://doi.org/10.1016/j.rmed.2009.06.014.
- Juniper EF, O′Byrne PM, Guyatt Gh, Ferrie Pj, King Dr. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi:https://doi.org/10.1034/j.1399-3003.1999.14d29.x.
- Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:https://doi.org/10.1016/j.jaci.2003.09.008.
- Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14(1):23–27. doi:https://doi.org/10.1034/j.1399-3003.1999.14a06.x.
- Shirai T, Akamatsu T, Hirai K, Watanabe H, Tamura K, Kishimoto Y, Saigusa M. Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma. Allergy. 2020;75(10):2678–2680. doi:https://doi.org/10.1111/all.14339.
- Kanda Y. Investigation of the Freely Available Easy-to-Use Software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:https://doi.org/10.1038/bmt.2012.244.
- Kavanagh JE, Hearn AP, Dhariwal J, d’Ancona G, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:https://doi.org/10.1016/j.chest.2020.08.2083.
- Renner A, Marth K, Patocka K, Idzko M, Pohl W. Benralizumab rapidly improves asthma control in Austrian real-life severe eosinophilic asthmatics. Allergy. 2020;75(12):3272–3275. doi:https://doi.org/10.1111/all.14441.
- Pelaia C, Busceti MT, Crimi C, Carpagnano GE, Lombardo N, Terracciano R, Vatrella A, Pelaia G. Real-life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020; 129:110444. doi:https://doi.org/10.1016/j.biopha.2020.110444.
- Padilla-Galo A, Levy-Abitbol RCh, Olveira C, Valencia Azcona B, Pérez Morales M, Rivas-Ruiz F, Tortajada-Goitia B, Moya-Carmona I, Levy-Naon A. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184. doi:https://doi.org/10.1186/s12890-020-01220-9.
- Hearn AP, Kavanagh J, d’Ancona G, et al. The relationship between FeNO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021; 9(5):2093–2096. doi:https://doi.org/10.1016/j.jaip.2021.01.008.
- Buhl R, Humbert M, Bjermer L, Chanez P, Heaney LG, Pavord I, Quirce S, Virchow JC, Holgate S, expert group of the European Consensus Meeting for Severe Eosinophilic Asthma Severe Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49(5):1700634. doi:https://doi.org/10.1183/13993003.00634-2017.
- Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. doi:https://doi.org/10.1183/13993003.01633-2019.
- Yamada H, Nakajima M, Matsuyama M, Morishima Y, Arai N, Hida N, Nakaizumi T, Masuko H, Yatagai Y, Saito T, et al. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. PLoS One. 2021;16(3):e0248305. doi:https://doi.org/10.1371/journal.pone.0248305.
- Katial R, Kreindler J, Hirsch I, et al. Blood eosinophil count and fractional exhaled nitric oxide as a combined predictor of treatment response to benralizumab for patients with severe, eosinophilic asthma. Pneumologie. 2021; 75(S 01):S34. doi:https://doi.org/10.1055/s-0041-1723324.75(34)
- Hirai K, Uehara S, Shirai T, Rachi Y, Kimura T, Akamatsu T, Itoh K. Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma. Allergy. 2021;76(8):2589–2592. doi:https://doi.org/10.1111/all.14819.